Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04281472
Recruitment Status : Recruiting
First Posted : February 24, 2020
Last Update Posted : October 5, 2020
Sponsor:
Information provided by (Responsible Party):
argenx

Brief Summary:
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

Condition or disease Intervention/treatment Phase
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Biological: efgartigimod PH20 SC in stage B Other: placebo in stage B Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Actual Study Start Date : April 15, 2020
Estimated Primary Completion Date : August 15, 2023
Estimated Study Completion Date : August 15, 2023


Arm Intervention/treatment
Experimental: efgartigimod PH20 SC
patients receiving efgartigimod PH20 SC in both stage A as stage B
Biological: efgartigimod PH20 SC in stage B
Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC

Placebo Comparator: Placebo
patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B
Biological: efgartigimod PH20 SC in stage B
Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC

Other: placebo in stage B
Stage A: N/A, stage B: placebo




Primary Outcome Measures :
  1. Stage A: Percentage of patients with confirmed evidence of clinical improvement(ECI) [ Time Frame: Up to 12 weeks during the open-label stage A ]
  2. Stage B: Time to first adjusted INCAT deterioration compared to Stage B baseline [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]

Secondary Outcome Measures :
  1. Stage A: Time to initial confirmed ECI [ Time Frame: Up to 12 weeks during the open-label stage A ]
  2. Stage A: Change from Stage A baseline over time in adjusted INCAT score [ Time Frame: Up to 12 weeks during the open-label stage A ]
  3. Stage A: Change from Stage A baseline over time in Medical Research Council (MRC) Sum score [ Time Frame: Up to 12 weeks during the open-label stage A ]
  4. Stage A: Change from Stage A baseline over time in I-RODS disability scores [ Time Frame: Up to 12 weeks during the open-label stage A ]
  5. Stage A: Change from Stage A baseline over time in TUG score [ Time Frame: Up to 12 weeks during the open-label stage A ]
  6. Stage A: Change from Stage A baseline over time in mean grip strength [ Time Frame: Up to 12 weeks during the open-label stage A ]
  7. Stage A: Exposure adjusted occurrence of treatment-emergent (serious) adverse events [ Time Frame: Up to 12 weeks during the open-label stage A ]
  8. Stage A: Incidence of clinically significant laboratory abnormalities [ Time Frame: Up to 12 weeks during the open-label stage A ]
  9. Stage A: Pre-dosing efgartigimod serum concentrations over time [ Time Frame: Up to 12 weeks during the open-label stage A ]
  10. Stage A: Changes of serum IgG levels over time [ Time Frame: Up to 12 weeks during the open-label stage A ]
  11. Stage A: Percentage of patients with and titers of binding antibodies towards efgartigimod and/or rHuPH20 and the presence of neutralizing antibodies against efgartigimod and/or rHuPH20 [ Time Frame: Up to 12 weeks during the open-label stage A ]
  12. Stage B: Time to CIDP disease progression [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
    Time to CIDP disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease ≥4 points compared to Stage B baseline using the centile metric.

  13. Stage B: Percentage of patients with improved functional level compared to Stage B baseline [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  14. Stage B: Change from Stage B baseline over time in adjusted INCAT score [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  15. Stage B: Change from Stage B baseline over time in MRC Sum score [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  16. Stage B: Change from Stage B baseline over time in 24-item I-RODS disability score [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  17. Stage B: Change from Stage B baseline over time in TUG score [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  18. Stage B: Change from Stage B baseline over time in mean grip strength [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  19. Stage B: Time to 10% decrease in the 24-item I-RODS [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  20. Stage B: Exposure adjusted occurrence of treatment-emergent adverse events and serious adverse events [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  21. Stage B: Incidence of clinically significant laboratory abnormalities [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  22. Stage B: Pre-dosing efgartigimod serum concentrations over time [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  23. Stage B: Changes of serum IgG levels over time [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]
  24. Stage B: Percentage of patients with and titers of binding antibodies towards efgartigimod and/or rHuPH20 and the presence of neutralizing antibodies against efgartigimod and/or rHuPH20 [ Time Frame: Up to 48 weeks during the randomized placebo-controlled stage B ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to understand the requirements of the trial, provide written informed consent (include consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits)
  2. Male or female patient aged 18 years or older, at the time of signing the informed consent.
  3. Diagnosed with probable or definite CIDP according to criteria of the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS 2010), progressing or relapsing forms.
  4. CIDP Disease Activity Status (CDAS) score ≥2 at screening.
  5. INCAT score ≥2, with a score of 2 exclusively from leg disability, at the first run-in visit (for patients entering run-in) or stage A baseline (for treatment-naïve patients with documented evidence for worsening on the total adjusted INCAT disability score within 3 months prior to screening)
  6. Fulfilling any of the following treatment conditions:

    • Currently treated with pulsed corticosteroids, oral corticosteroids equivalent to prednisolone/prednisone ≤10mg/day, and/or IVIg or SCIg, if this treatment has been started within the last 5 years before screening, and the patient is willing to discontinue this treatment at the first run-in visit; or
    • Without previous treatment (treatment-naive); or
    • Treatment with corticosteroids and/or IVIg or SCIg discontinued at least 6 months prior to screening Note: Patients not treated with monthly or daily corticosteroids, IVIg or SCIg for at least 6 months prior to screening are considered as equal to treatment-naïve patients.
  7. Women of childbearing potential who have a negative pregnancy test at screening and a negative urine pregnancy test up to Stage A baseline.
  8. Women of childbearing potential must use a highly effective method of contraception (failure rate of less than 1% per year) from screening to 90 days after the last administration of IMP
  9. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom and his partner must use a highly effective method of contraception (failure rate of less than 1% per year) from screening to 90 days after the last administration of IMP. Male patients practicing true sexual abstinence (when this is in line with the preferred and usual life style of the participant) can be included. Sterilized male patients who have had vasectomy with documented aspermia post-procedure can be included. In addition, male patients are not allowed to donate sperm from screening to 90 days after the last administration of IMP

Exclusion Criteria:

  1. Pure sensory atypical CIDP (EFNS/PNS definition).
  2. Polyneuropathy of other causes, including the following: Multifocal motor neuropathy; Monoclonal gammopathy of uncertain significance with anti-myelin associated, glycoprotein immunoglobulin M (IgM) antibodies; Hereditary demyelinating neuropathy; Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy.
  3. Any other disease that could better explain the patient's signs and symptoms.
  4. Any history of myelopathy or evidence of central demyelination.
  5. Current or past history (within 12 months of screening) of alcohol, drug or medication abuse.
  6. Severe psychiatric disorder (such as severe depression, psychosis, bipolar disorder), history of suicide attempt, or current suicidal ideation that in the opinion of the investigator could create undue risk to the patient or could affect adherence with the trial protocol.
  7. Patients with clinically significant active or chronic uncontrolled bacterial, viral, or fungal infection at screening, including patients who test positive for an active viral infection at screening with: Active Hepatitis B Virus (HBV): serologic panel test results indicative of an active (acute or chronic) infection; Active Hepatitis C Virus (HCV): serology positive for HCV-Ab; Human Immunodeficiency Virus (HIV) positive serology associated with an Acquired Immune Deficiency Syndrome (AIDS)-defining condition or with a cluster of differentiation 4 (CD4) count ≤200 cells/mm3.
  8. Total IgG level <6 g/L at screening.
  9. Treatment with the following: Within 3 months (or 5 half-lives of the drug, whichever is longer) before screening: plasma exchange or immunoadsorption, any concomitant Fc-containing therapeutic agents or other biological, or any other investigational product; Within 6 months before screening: rituximab, alemtuzumab, any other monoclonal antibody, cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, methotrexate, azathioprine, mycophenolate, any other immunomodulating or immunosuppressive medications, and oral daily corticosteroids >10 mg/day. Note: Patients using IVIg, SCIg, pulsed corticosteroids, and oral daily corticosteroids ≤10 mg/day can be included.
  10. Pregnant and lactating women and those intending to become pregnant during the trial or within 90 days after last IMP administration.
  11. Patients with any other known autoimmune disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of CIDP.
  12. Patients who received a live-attenuated vaccine fewer than 28 days before screening. Receiving an inactivated, sub-unit, polysaccharide, or conjugate vaccine any time before screening is not exclusionary.
  13. Patients who have a history of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before the first IMP administration. Patients with the following cancer can be included anytime: Adequately treated basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, or Incidental histological finding of Prostate cancer (TNM [tumor, nodes, and metastases classification] stage T1a or T1b).
  14. Patients who previously participated in a trial with efgartigimod and have received at least one administration of IMP.
  15. Patients with known medical history of hypersensitivity to any of the ingredients of IMP.
  16. Patients with clinical evidence of other significant serious disease or patients who underwent a recent or have a planned major surgery, or any other reason which could confound the results of the trial or put the patient at undue risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04281472


Contacts
Layout table for location contacts
Contact: Antonio Guglietta, MD +1 857-350-4834 ClinicalTrials@argenx.com

Locations
Show Show 37 study locations
Sponsors and Collaborators
argenx
Layout table for additonal information
Responsible Party: argenx
ClinicalTrials.gov Identifier: NCT04281472    
Other Study ID Numbers: ARGX-113-1802
2019-003076-39 ( EudraCT Number )
First Posted: February 24, 2020    Key Record Dates
Last Update Posted: October 5, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Polyneuropathies
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Polyradiculoneuropathy
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases